Summary For Health Professionals

ENERCEL® SUMMARY FOR HEALTH PROFESSIONALS

I.   PRECLINICAL SAFETY DATA

TOXICITY

In vitro

Enercel® at a dose of 100 µl/mg was applied to confluent monolayers of both MOLT-5 and K562 cells. 5% ethanol was applied to control plates. Tissue culture media with fresh Enercel® at 100 µl/mg was added daily. The cells were observed for necrosis for 3 days. There was no toxicity (0 on a scale of 5).

Animals

Either placebo (5% ethanol) or Enercel® at a dose of 0.35 cc SQ was administered to 10 mice per group for 28 consecutive days. The animals were observed clinically each day for toxicity. There was no ataxia, lethargy or respiratory distress. After 28 days, sections of harvested brains, kidneys, livers, pancreases and hearts were examined for inflammation and/or necrosis. None was found. A repeat study using the same parameters was performed.  Again, there was no clinical or microscopic toxicity.

Rats with experimentally-induced mammary gland tumors were treated with Enercel®, 0.05 to 1 ml IM/day. Control animals were given 1 ml placebo IM. No tissue necrosis was noted in biopsies from either group.

Mice were treated with 0.5 ml IM Enercel® daily for 30 days and evaluated for clinical and microscopic toxicity. There were no changes in color of the mucous membranes, hair, tail scaling, diarrhea, oral intake, movement, or posture. After sacrifice, internal organs were normal as to gross appearance, size, consistency, weight and blood vessels. Microscopic evaluation did not show any toxicity.

 

 

II.       RESULTS OF CLINICAL AND ANIMAL EFFICACY STUDIES OF ENERCEL®

       A.   Immunomodulatory Effects of a Homeopathic Agent.

See DM, Tilles JG, Bertacchini C

Either 5% ethanol placebo or Enercel® was administered to groups of adolescent CD-1 mice at a dose of 0.35 cc SQ daily for 28 days.  None of the mice manifested any evidence of gross or microscopic toxicity (brains, kidneys, livers, pancreases, or hearts).  Splenic Natural Killer (NK) function versus YAC-1 targets was significantly greater in mice treated with the homeopathic agent Enercel® (mean 103 +/- 10.9 lytic units [LU]; p<.05) compared to placebo (mean 81 +/- 7.4 LU).  Groups of mice were treated with 21, 14, 7, or 0-day courses of Enercel® tincture or placebo.  They were then challenged with 1 x 104 plaque-forming units (PFU) of a diabetogenic strain of coxsackie virus B4 (E2).  Treatment was continued for an additional three days; then the mice were sacrificed.  Titers of virus in the pancreas were significantly reduced in the homeopathic group that was treated for 21 days prior to viral challenge (mean [log 10] 3.14 +/- 0.79 pfu/mg; p<.05) compared to placebo (mean [log 10] 4.29+/- 0.90 pfu/mg). Thus, a homeopathic medication, Enercel®, increased NK function both in vitro and in vivo and was non-toxic to mice.  In vivo antiviral activity was demonstrated, presumably through immune enhancement.

      B.    Effect of Enercel® on Acute Documented or Presumed Infectious Diarrhea in Children Less Than 5 Years of Age at the Emergency Ward of B. Bloom Hospital in San Salvador. 

Izaguirre RR, Guzmán, MR, Fuentes, RC, Mena CE, Peñate E.

AIMS: The homeopathic medicine Enercel® was tested in acute cases of presumed or documented infectious diarrhea in children less than 5 years of age. A total of 123 cases were evaluated– 59 in the control (observation) group and 64 in the test (Enercel®) group. Test subjects received 3 ml IM doses at baseline and 12 hours. Patients with parasitic and non-infectious causes of diarrhea were excluded. A clinical score to determine improvement or deterioration was created and applied to both groups. Statistical analysis was worked through EPI-INFO and SPSS programs. Clinical changes were measured every 6 hours for the first 24 hours, then again at 72 post-enrollment.

RESULTS: Both groups were comparable statistically in terms of clinical presentation, demographics and laboratory findings on enrollment. Differences in clinical status score became significant at 18 and 24 hours (p < 0.05) and more so at 72 hours after enrollment (p < 0.01). The Enercel®-treated group had significant improvement in fecal output at 12 – 18 hours and 18 – 24 hours (p < .01 for both). Seventeen subjects in the control and 15 in the test group had rotavirus infection. There was a borderline significant difference in clinical status at 18 hours (p = 0.08) and 24 hours (p = 0.06) after enrollment. At 72 hours, however, the difference was significant (p < 0.01).

CONCLUSIONS: Enercel® was effective in limiting clinical manifestations of infectious diarrhea in children < 5 years old. Such infections result in considerable morbidity and mortality in underdeveloped countries. The rotavirus infection subgroup responded more slowly, but the difference between control and test groups was significant at 72 hours. Enercel® may be a candidate as an inexpensive, completely safe alternative to antibiotic or symptom-only treatment of acute documented or presumed infectious diarrhea in children from developing nations.

C. Enercel®: A New Homeopathic Immune Enhancer Nasal Spray For Recurrent Allergic Disease Of The Upper Respiratory Tract: A Preliminary Communique. Izaguirre RR

A total of 30 cases, ages from 8 months to 82 years were enrolled. Each subject had the clinical diagnosis of recurrent allergic rhinitis, sinusitis and/or bronchitis. The protocol included a standard dose of two sprays of Enercel® Mist in each nostril three times per day in patients above five years of age; one spray three times per day in patients between two and five years of age; and one spray twice per day for infants under two years of age.  Clinical parameters followed were: sneezing, runny nose, nasal congestion, wheezing, hypertrophy of adenoidal tissues; infections and antibiotic use, cough, weight loss, fever, and frequency, duration and severity of relapses and the patient’s sense of well being. Subject response were graded from 1 to 4 on a clinical scale, with 1 being no response and 4 an excellent response. The use of Enercel® Mist Nasal spray favorably influenced allergic-originated upper respiratory tract recurrent disease with a score of 3 out of 4 (good) in 34.5% of the cases.  Excellent results (4/4) were recorded in an additional 58.6% of subjects for an overall positive response in 93.1%.  The clinical response was more pronounced  in patients below 30 years of age. No adverse reactions were reported in any case.

D. Can Wasted Muscle be Rehydrated and Functionally Enhanced?

     Hazlewood CF, Kereszti L.

In a pilot study, patients with atrophied muscles were injected with a Biological Response Modulator (Enercel®). The solution was injected into the motor points of the atrophied muscles. Within 24 – 48 hours, the volume of the treated muscles was increased.

E. Application Of Enercel® Mist, A Homeopathic Nasal Spray, In Cases Of Allergic Origin Otorhinological Diseases.

Kereszti GO

Eighty-two patients at an ENT outpatient clinic were sequentially enrolled into the study.  These subjects all had seasonal and perennial allergic rhinitis, confirmed with a prick test. The age of the patients ranged from 3 to 66 years. The number of patients under 14 years was 33 (39.3%), the number of adult patients were 49 (59.8%). Thirty-two percent (32%) of the patients had skin lesions and all patients had accompanying lower respiratory symptoms. One third of the patients were previously treated with other antiallergenic therapy. Enercel® Mist Nasal spray was delivered in 2 puffs, 4 times a day to both nostrils. Subjects were seen 1 week and 1 month after the initiation of treatment, at which time clinical examinations were done. They were also questioned about their symptoms and possible side effects. The symptoms of allergic rhinitis (congestion, itching, dripping, tearing, eye irritation) showed significant improvement (p <0.01) at 1 week and was maintained throughout the treatment. Some peripheral manifestations of allergies like atopic dermatitis and urticaria also improved. Obstructive airway symptoms (wheezing, coughing at rest and at exertion, shortness of breath) also improved significantly at 1 week on the symptomatic score index and it was maintained at one month.

F. Aspects of the Quality Of Life in Patients with Advanced Pancreatic Cancer. Bertacchini C. 

Eighty-seven patients with stage III or IV pancreatic cancer were enrolled in this trial. A questionnaire was devised to measure selective aspects of quality of life.  A survival curve was analyzed; and group follow-up was for twelve months. Daily doses of Enercel® 4 cc IM were administered during the entire study period. Sublingual and oral doses were also added for an additional 2.5 cc administered in four daily doses. A significant, beneficial effect was noted on several clinical parameters:  pain, appetite, nausea and vomiting, emotional state and physical function. Compared with historical controls with this stage and type of cancer, 1-year survival was significantly improved. Sixty subjects were still alive at 1 year.  The results of this study revealed that patients with advanced pancreatic cancer treated for 1 year with Enercel® had a significant improvement on selective aspects of quality of life and survival compared to historical controls.

G. Enercel® In Vivo Studies on Experimental Tumors.

Bergoc RM, Rivera ES

The efficacy of Enercel® in the treatment of induced mammary tumors in rats was evaluated. Escalating IM doses up to 1 ml/day for 10 days were assessed. After 10 days, the animals showed a clear improvement in their general wellness as manifested by greater mobility, friskiness and an increase in body weight as compared to placebo-treated controls. Tumor growth was arrested, and sometimes regressed, in a high proportion of lesions in the treated rats. Some tumors developed a characteristic central lesion consistent with tumor breakdown on histopathologic specimens. Statistical evaluation demonstrated that the survival of the test animals was significantly greater than that of the controls (p <0.01). The clinical and pathologic benefits of Enercel® were dose-dependent. There was no difference in end points between animals treated with low-dose (0.05 ml/day) Enercel® than in untreated controls. Thus, Enercel® treatment was beneficial in a rat model of induced mammary tumors in a dose-dependent fashion. All but the lowest dose was successful. Tumor regression, improved clinical signs and greater survival were observed in treated animals compared to no response in placebo-treated ones.

H. Significant Neurological Improvement in Two Patients with Amyotrophic Lateral Sclerosis after 4 Weeks of Treatment with Acupuncture Injection Point Therapy Using Enercel®.

S. Liang DOM, D. Christner MD [MA], PhD, S. Du Laux MD[MA], D. Ac,

D. Laurent MD

Amyotrophic Lateral Sclerosis (ALS) is a progressive, uniformly fatal, degenerative disorder of upper and motor neurons without any current effective treatment. We report on two case-studies of patients with ALS treated with 4 weeks of Acupuncture injection point therapy using Enercel®. Two patients with advanced ALS were given Enercel® Plus IM 0.25 to 0.5 cc at specific Acupuncture points 5 days per week for 4 weeks. Patient #1 presented with flaccid paralysis of all 4 extremities and impaired speech and swallowing. By week 4, she had significant improvement in motor strength of all 4 extremities, R > L, and improvements in speech and swallowing. She did not continue EnercelÒ Acupoint injections and had slow, progressive loss of neurological function during 3 months of follow-up. Patient #2 had significantly impaired speech and mild motor loss in both upper extremities and left leg. After 4 weeks, his voice had significantly improved to the point that his speech was understandable and his motor function had returned to normal. He continued EnercelÒ Acupoint injections during the 3-month follow-up and the clinical improvement was retained. Thus, two patients with ALS improved after 4 weeks of Enercel® Acupoint injection therapy. Follow-up data suggests that ongoing therapy may be necessary in order to maintain the positive effects. This preliminary data merits further study and confirmation.

 

 

I.      Phase III Study of Four Weeks Treatment with Enercel® for New-onset, Presumed Drug-sensitive and Ten Weeks Therapy for Confirmed, Treatment-Refractory, Multi-drug Resistant Pulmonary Tuberculosis at the Regional Antituberculosis Hospital in Chernigov, Ukraine.

Dubrov V, Dubrov T, Suhareva V, Christner D, Baiamonte J, Laurent D, Sanseverino S

OBJECTIVE: To determine if the complex homeopathic medicine Enercel® is efficacious in short-term treatment of new-onset, presumed drug-sensitive and confirmed multi-drug resistant [MDR-TB] pulmonary tuberculosis [TB].

MATERIALS AND METHODS: Seven new-onset, presumed drug-sensitive pulmonary TB and eight MDR-TB patients were enrolled. They each had baseline AFB-positive sputum smears. Drug-sensitive patients were treated with Enercel® by intravenous, aerosolized, sublingual and intranasal routes for 30 consecutive days. MDR-TB patients were treated for 10 consecutive weeks. Endpoints included Chest X ray, sputum AFB smears and Quality of Life [QOL] evaluation as assessed by cough, energy, mood, appetite, night sweats, weight and ease of breathing. Safety of Enercel® was evaluated by complete blood count and liver function testing.

RESULTS AND DISCUSSION: Seven of seven [100%] presumed drug-sensitive patients were sputum AFB smear negative after 30 days. The 7 patients also had significantly decreased infiltrates and cavitations by Chest X ray. QOL significantly improved in all 7 patients. Four of eight [50%] MDR-TB patients were AFB smear negative and 1 more [12%] had significantly less AFB-positive organisms after 10 weeks. Each of these 5 responders had significantly improved Chest X ray findings. QOL significantly improved in each of the 8 patients. There were no toxicity or side effects associated with Enercel® use.

CONCLUSIONS: Enercel® was highly effective in a short time [30 days] for new-onset, presumed drug-sensitive pulmonary TB and 10 weeks for confirmed MDR-TB patients. There were no adverse events associated with Enercel® administration. Enercel® may be useful in improving outcomes, limiting mortality, improving general health, and reducing length of treatment in these populations. Finally, long-term medical costs to public health systems may be significantly reduced.

III.            UNDESIRABLE EFFECTS

Enercel® has no known toxicity—therefore, no specific laboratory studies are required. Testing should reflect the disease state itself and not the application of Enercel®.

Enercel® has been used in a single dose up to 100 ml intravenously without side-effects. It has also been taken multiple times per day for many years without adverse effects. Any potential side-effects are related to the route of administration and not to Enercel® itself. Enercel® IV may result in bleeding, bruising, pain and risk of infection at the site of administration.

Once-hundred twenty-three children less than 5 years of age were enrolled in a placebo-controlled study of acute diarrhea disease. The test group received 3 ml IM of Enercel® twice daily for two total doses. No clinical signs of toxicity were noted.

A single-dose study of Enercel® –100 ml intravenously– was performed. No clinical or laboratory evidence of toxicity was noted.

Eighty-two patients were treated with Enercel® Mist Nasal spray 2 puffs three times/day for 1 month. No adverse reactions were noted.

IV.      PARTICULARS OF ADMINISTRATION

Duration of therapy

The duration of therapy of Enercel® products is variable, depending on specific conditions and response to treatment. Clinical response to Enercel® has been observed within 2-3 hrs. A study of acute diarrhea in children reported resolution of symptoms in the majority of recipients after just 2 IM doses 12 hrs apart. Patients with pancreatic cancer were treated for 1 year with Enercel® given by IM, sublingual and oral routes. For many chronic conditions, Enercel® has been used daily for years without side effects or toxicity. Up to 50 ml of Enercel® Plus IV has been given intravenously on a daily basis for prolonged periods of time in patients with more serious illnesses without adverse effects. It is recommended that, for severe disorders, Enercel® IV be given 10 consecutive days followed by 2 days of detoxification in cycles as determined by clinical status.

 

Rate of administration

Enercel®  Plus I.V.—qd to q12hrs

 

Special populations

Patients with kidney/liver insufficiency: There are no known adverse effects in patients with hepatic or renal disease. Enercel® has been extensively used in these populations without problems. No dosage interval changes are required.

Elderly patients

Although the pharmacokinetic disposition of Enercel® in the elderly is similar to those seen in younger adults, there is no targeted clinical trial data about the safety and effectiveness of Enercel® in this population. Subgroup analysis of elderly subjects in clinical trials reveals a  similar clinical response and lack of toxicity as in younger adults. Enercel® has been used in thousands of elderly patients in open-label use without side effects and with clinical efficacy. Enercel® can be used safely and efficaciously in the elderly population.

Children

The World Health Advanced Technology, Ltd. database contains hundreds of anecdotal reports of children receiving Enercel® without toxicity or side effects.  Children have used the medication chronically with no side-effects or developmental delays. These include children with severe illnesses such as pneumonia and copious diarrhea. A formal study of Enercel® at 3 ml IM every 12 hrs. for two doses in a Pediatric population failed to show any local or systemic toxicity. A study of Enercel® Mist Nasal in allergic upper respiratory disorders included a large number of children without side effects. The IV route has been used in children up to 2 ml/kg/day– again, no toxicity was noted. There are no known limitations on the use of Enercel® in infants and children.

Contraindications

Enercel® has been used safely and effectively in patients with chronic diseases including;  heart disease; renal insufficiency; liver disorders; immunodeficiencies; autoimmune conditions; cancer; nervous system diseases and chronic infections. There are no known contraindications for Enercel®.

V.       MECHANISM OF ACTION

Professor Luc Montagnier is a French virologist who co-discovered HIV and who won the Nobel Prize in 2008.  Dr. Montagnier has received many other significant awards, though his newest research, which may explain how and why homeopathic medicines maintain their biological activity in extreme dilution, may be his most significant to date.

In a recent paper, Prof Montagnier and his team report the results of a series of rigorous experiments investigating the electromagnetic (EM) properties of highly diluted biological samples. 

The abstract of this research in part asserts, “A novel property of DNA is described: the capacity of some bacterial DNA sequences to induce electromagnetic waves at high aqueous dilutions.  It appears to be a resonance phenomenon triggered by the ambient electromagnetic background of very low frequency waves.”

Although homeopathy is not mentioned anywhere in the article, the researchers used aqueous solutions that were agitated and serially diluted (the researchers note that the solutions were “strongly agitated” and that this step was “critical for the generation of signals”).  The researchers also note that they used a device made by French immunologist Jacques Benveniste (the famous physician/scientist who conducted studies testing homeopathic doses and whose work was initially published in Nature, and then, it was “debunked” in that same journal a month later). 

The researchers found that pathogenic bacteria and viruses show a distinct EM signature at dilutions ranging from 10-5 to 10-12 (corresponding to 5X to 12X) and that small DNA fragments (responsible for pathogenicity) were solely accountable for the EM signal.

The researchers also noted that one experiment found significant effects from dilutions as high as 10-18 (equivalent to 18X).  The EM signature changed with dilution levels but was unaffected by the initial concentration and remained even after the remaining DNA fragments were destroyed by chemical agents.  Of additional interest was the researchers’ observation that they observed the same results whether their initial concentration of cells were just 10 or 109.

They observed that the EM signal was destroyed by heating or freezing the sample (a common observation that homeopaths have also found in their medicines).  Also, a ‘cross-talk’ effect was found whereby a negative sample inhibits the positive signal in another sample if they are left together overnight in a shielded container. The researchers propose that specific aqueous nanostructures form in the samples during the dilution process and are responsible for the EM effects measured. 

The researchers also detected the same electromagnetic signals in the plasma and in the DNA extracted from the plasma of patients suffering from Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and rheumatoid arthritis.

The researchers also quote Italian physicist, E. Del Guidice, the same scientist whom Benveniste cited, for positing that water molecules can form long polymers of dipoles associated by hydrogen bonds and that electromagnetic radiations that they emit enable them to avoid decay. 

With this initial paper, Prof Montagnier and his team have started a very promising line of enquiry, which has direct relevance to homeopathy as they continue to investigate the characteristic physico-chemical properties found in high-dilutions of biological material. 

Reference:  Luc Montagnier, Jamal Aissa, Stéphane Ferris, Jean-Luc Montagnier, Claude Lavallee, Electromagnetic Signals Are Produced by Aqueous Nanostructures Derived from Bacterial DNA Sequences.  Interdiscip Sci Comput Life Sci (2009) 1: 81-90.

VI.      ENERPUNCTURE: THE COMBINATION OF ENERCEL® WITH ACUPUNCTURE

Enercel® and Acupuncture have been shown to be efficacious in a number of disorders due to stimulation and modulation of specific internal and external energy pathways.  Preliminary case-reports suggest that the combination may be synergistic in supporting organ, tissue and especially immune system function, presumably through energy modulation. This report primarily deals with the effect of Enercel® and Acupuncture—individually and in combination—on neurodegenerative disorders and neuropathies.

Energy Medicine is based upon the belief that changes in the “life force” of the body– including the electric, magnetic, and electromagnetic fields—can affect human health, and can be manipulated to promote healing.  Alternatively, a new concept of Energy Medicine embodies a network of under-differentiated, electromagnetically sensitive cells in the body that can be “triggered” by energetic substances to induce tissue repair and regeneration.

The notion of a life force or energy is shared by people around the world.  Since ancient times, traditional cultures have believed that a special energy vitalizes all life. This Energy has many other names. It is intriguing to consider that this ancient concept of Bio-Energy may now be in the process of scientific definition as stem cell-like, electromagnetically sensitive cells in the body capable of cellular reconstruction and restoration.

Over the course of the past three decades, Energy Medicine has moved from being a marginal area of research to gaining a large measure of mainstream acceptance.  Despite over 300 studies during the past 40 years showing the efficacy of energy healing, these findings are still ignored or rejected by many scientists based on non-reproducible and inconsistent results.  Distinct among modalities that improve and modulate energy in the body,  Enercel® has proven to have reliable, reproducible, consistently positive results in clinical, animal and in vitro studies.

ENERCEL® is a combination of homeopathics as per the Homeopathic Pharmacopoeia of the United States (HPUS).  Enercel® has been proven to be completely non-toxic and without negative side effects in patients both in clinical trials and general use. It is thought to work in the body by support of tissue and organ function via intra- and extracellular energy stimulation.

Enercel® activates the energy pathways of tissues throughout the body.  The energy enhancement in the tissues results in improved function, health, metabolism and resistance to infection and stress.  Once the energy of cells is normalized, particularly in the immune system, their health is restored and they are able to carry on their normal activities.  Furthermore, since all tissues in a local area are affected in this way, homeostasis, not just of cells but between cells as well, is restored.  When cells have sufficient and regulated energy, their function is modulated—when overactive, they quiet, and when underactive, they increase their activity.  Overall, Enercel® enhances the substrate of cells of the body in order to re-set them for optimal function. In particular, the immune system is effectively regulated. The turn-over of immune cells in areas of infection, inflammation, oxidation and/or necrosis is intense.  Homeostasis is difficult to achieve in such a milieu. Enercel® encourages self-modulation of immune function and the re-establishment of normal cellular, tissue and organ function. Symptoms of hypo- and hyperimmunity are reduced; infections are effectively fought; tissue damage is repaired; and pain and inflammation are diminished.

Enercel® has been successfully used in the management of neurodegenerative disorders.

 

Case report #1: A 40 year-old female suffered lower back trauma from a motor vehicle accident.  Subsequently she developed progressive weakness in her lower extremities, numbness in both feet, calf and feet muscle atrophy and a clumsy gait.  A spine MRI showed spinal stenosis.  She underwent back surgery to repair the stenosis—this resulted in a slower progression of lower extremity neurological symptoms but no regression.  She remained dependent on crutches.  Two years later, she began Enercel® by oral, IM and sublingual routes and by subcutaneous injection at specific Acupuncture points.  She showed slow improvement over a three-month period of daily administration of Enercel®.  At the end of that time, she was able to walk without crutches and had normal sensation in her feet.

 

Case report #2: A 70 year-old female developed right eye pain, swelling of the area around the eye and blisters on the forehead, which progressed over 3-4 days.  A diagnosis of ophthalmic herpes zoster was made.  She then began to suffer from right-side headaches, tingling, and pain over her eye consistent with post-herpetic neuralgia.  She began Enercel® Mist administration to her right eye every 2-3 hours as well as Enercel® intravenously (once daily) for 5 days.  The swelling and eye pain began to quickly improve and then resolved.  More significantly, her neurogenic headaches and supraorbital pain gradually diminished and then resolved over about 7 days.

ACUPUNCTURE is a technique of traditional Chinese medicine, in which a number of very fine metal needles are inserted into the skin at specially designated points.  For thousands of years acupuncture has been used, along with herbal medicine, for pain relief and treatment of various ailments. Today it is widely used in China in the treatment of hay fever, headaches, and ulcers, and some types of blindness, arthritis, diarrhea, and hypertension. Acupuncture is also used, especially in China, as a general anesthetic during childbirth and some types of surgery.

Generally, in the practice of acupuncture, needles varying in length from 1/2 in. (1.27 cm) to several inches are inserted in appropriate points of the body, not necessarily near the affected organ.  The needles are twirled and vibrated in specific ways; the depth of insertion also affects the treatment. Modern technique sometimes adds electrical stimulation applied through the needles. The traditional acupuncture points (about 800) are arranged along 14 lines, or meridians, running the length of the body from head to foot.

The traditional Chinese explanation of the effectiveness of acupuncture is based on the Taoist philosophy according to which good health depends on a free circulation of chi (qi), or life-force energy, throughout all the organs of the body.  The chi, in turn, depends upon a balance of the two opposing energies of yin (negative, dark, feminine) and yang (positive, bright, masculine). The meridians are the main channels of flow. When energy flow is impeded at any point, e.g., because of a diseased organ or stress, illness in other organs may result. Piercing the channels at the proper points is believed to correct the imbalances.

Western researchers have found that the acupuncture points correspond to points on the skin having less electrical resistance than other skin areas.  It has been suggested that acupuncture works by stimulating or repressing the autonomic nervous system in various ways, and there is some evidence that stimulation of the skin can affect internal organs by means of nerve reflex pathways. One theory is that acupuncture stimulates the release of natural pain-relieving chemicals called endorphins.  Another is that it stimulates the pituitary gland, which in turn stimulates the adrenal gland to release anti-inflammatory chemicals.

Since the early 1970s, acupuncture has gradually become more accepted in the United States.  Many states now accredit schools of acupuncture and administer licensing examinations for non-physicians. Some physicians are studying and using acupuncture as an adjunct treatment. In the United States acupuncture has been used most often for pain control and drug and alcohol addiction. One impediment to total acceptance is the difficulty of fitting a traditional technique from another culture into the strict methods of scientific clinical trials customary in Western medicine. However, a number of clinical trials have suggested that Acupuncture is efficacious for a number or disorders including neurodegenerative disorders and neuropathies.

Several studies have suggested that Acupuncture is beneficial in peripheral neuropathies.  One study of acupuncture in treating diabetic peripheral neuropathy involved 60 participants.  The study found that those receiving acupuncture had a statistically greater improvement in neurological symptoms as well as improved nerve function for both sensory and motor nerve conduction when compared to the control group.  Another study conducted in Africa found that for the 126 patients that received acupuncture for diabetic peripheral neuropathy, 86% deemed the treatment as being effective for reducing symptoms in their hands and feet.

In a 2006 Canadian study, acupuncture was utilized in five cases to reduce neuropathic pain in cancer patients.  The acupuncture treatment was deemed effective in these cases where medication had failed.  And finally, in a Chinese study involving 90 participants, those receiving total body or wrist and ankle acupuncture has significantly improved blood sugar and lipids, decreased blood viscosity, and improved functions of peripheral nerve cells, thus resulting in therapeutic effects for diabetic peripheral neuritis when compared to the control group.  The study also found no significant difference between the total body group and the ankle and wrist treatment group.

ENERCEL® TOGETHER WITH ACUPUNCTURE

The injection of liquid products into Acupuncture points—both drug and natural—labeled Acupuncture Injection Point Therapy (AIPT).  The treatment is based on the concept that products that enhance energy channels may work synergistically with Acupuncture.  Animal trials have validated the process in several models, including bee venom acupoint injections for adjuvant-induced arthritis.  Although few clinical trials are yet available, extensive experience in the community—especially in China—has yielded results beyond what may be achievable by Acupuncture or the drug/supplement in question alone.  This practice is a recognized procedure in several states (Florida, Arkansas, Colorado, New Mexico, and Washington).

The administration of Enercel® into Acupuncture points has been named Enerpuncture™.  This procedure has been of benefit for multiple patients with a variety of illnesses, most commonly musculoskeletal.  Clinical experience to date has suggested that Acupoint injection with Enercel® may improve outcomes for many disorders compared to Acupuncture alone.  Furthermore, Enerpuncture™ was successfully administered to multiple patients with a variety of neurodegenerative disorders and neuropathies.

VII.     CANCER AND ENERGY

Within the human body, each cell registers an electrical charge across the cell membrane.  Each cell’s interior carries a negative charge respective to the exterior charge.  This electrical charge is referred to as the transmembrane potential.  The magnitude of the transmembrane charge is different from cell to cell, ranging from about -50 to -70 millivolts.  In cells that are excitable (chargeable), it can be even less than -70 millivolts.  Cancer cells are proven to contain low amounts of energy, have a reduced transmembrane potential, and a low level of cellular energy production.

 

The transmembrane potential in cancer cells is about -15 millivolts, indicative of extremely low energy levels.  Such cells with low energy have a strong tendency to divide into two separate cells.  The reason for this is quite simple: as the intracellular energy drops to low levels, the existence of the cell is threatened and it is at risk for apoptosis or cell death.  The cell then begins to proliferate uncontrollably in an attempt to save itself.  As these low-energy, cancerous cells continue to rapidly proliferate, the amount of energy that is produced within the progeny cells is even further diminished.  As one could imagine, the new cells that are formed have even more reduced levels of energy than the initial cancer cells.

 

Cancer cells begin to form in an area of the body that is already low in energy levels.  Researchers found a connection between mitochondria and cancer back in the 1930’s.  What was discovered was that mitochondria become dysfunctional in cancer cells.  Based on research done at the University of Alberta, cancer growth can be hindered by facilitating the production of energy within the mitochondria.  Early theories stated that the mitochondria in cancer cells are permanently damaged and not treatable.  However, current research is now showing that damaged mitochondria can be restored, and when they are, there is a reduction in tumor growth.

 

These findings point to dysfunctional mitochondria—and a resultant low-energy state—as a direct causal factor in the growth of cancer.  These conclusions have been confirmed in both in vitro and animal studies.  Enercel® helps to restore normal mitochondrial energy production, raising the energy production of the cells and normalizing the transmembrane potential.  As normal energy production is restored in cancerous cells, they no longer feel threatened, and they do not proliferate uncontrollably in an attempt to ensure their survival.  In turn, this process may arrest the proliferation of cancerous cells.

 

VIII.    ENERCEL® AND STEM CELLS

 

Recent studies have suggested that a population of stem cells are electromagnetically sensitive.  That is, certain electromagnetic frequencies [EMF] stimulate the proliferation of stem cells.  Patents for the application of electric and/or electromagnetic frequencies to stem cells have been filed.  Furthermore, preliminary studies have suggested that Enercel® —a potent homeopathic biological electromagnetic energy inducer—can prolong the life-span and induce proliferation of peripheral blood mononuclear cells [PBMC] and mesenchymal stem cells [private communication, Christner].  The highly diluted biological components of Enercel® appear to activate in vivo and in vitro electromagnetic signals.


 

IX.        DISCLAIMER

 

Enercel® is a homeopathic formulation manufactured in strict conformity with the Homeopathic Pharmacopoeia of the United States (HPUS). Enercel® is not FDA approved for any medical condition and no claims are made that it can treat, cure, mitigate or prevent any illness.

 

 

 

 

 

 

Glossary

Molt 5  Cells that are more stable than   MOLT 4 cells;  are lymphoblast-like in morphology and are used for studies of apoptosis, tumor cytotoxicity, tumorigenicity, as well as for antitumour testing.

 

K562 (Human erythromyeloblastoid leukemia cell line) K-562 is an erythroleukemia cell line derived from a chronic myeloid leukemia patient in blast crisis. Recent studies have shown the K562 blasts are multipotential, hematopoietic malignant cells that spontaneously differentiate into recognisable progenitors of the erythrocyte, granulocyte and monocytic series. Cells are also used for haemoglobin synthesis, antitumour testing, tumorigenicity, differentiation, pharmacodynamics, cloning, cytotoxicity, cell biology, cellular effects of hyperthermia, and natural killer assays.

 

The CD1 mouse is a multipurpose research animal model that can be used in such fields as toxicology (safety and efficacy testing), aging and oncology.

 

YAC1 is a T cell lymphoma which was induced by inoculation of the Moloney leukemia virus (MLV) into a newborn A/Sn mouse.

 

Coxsackie B4 virus is a virus which can trigger an autoimmune reaction which results in destruction of the insulin-producing beta cells of the pancreas, which is one of several different etiologies of diabetes mellitus.

 

Epi Info is public domain statistical software for epidemiology developed by Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia (USA).

 

SPSS  is among the most widely used programs for statistical analysis in social science.

 

otorhinology /oto·rhi·nol·o·gy/ (-ri-nol´ah-je) the branch of medicine dealing with the ear and nose. o·to·rhi·nol·o·gy ( t -r n l -j ). n.

 

AFB  acid-fast bacilli  Sputum smears or cultures.

 

QD or qd  means once daily.   Q12h or q12hrs means every twelve hours.

 

Enquiry:  a variant of inquiry.  A query is a single question; an inquiry (or enquiry) may be a single question or extensive investigation (i.e. a series of questions).

 

© 2017 Enercel | Nature Advanced - Disclaimer | Privacy Policy | Terms of Service
Top